Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients

Exclusion Criteria

• •Use of any HCV treatment ≤ 3months prior to study start
• •Prior receipt of any investigational anti-HCV therapy which is not IFN or RBV
• •Women of child-bearing potential unless they are post-menopausal or use predefined acceptable methods of contraception
• •Pregnant or breastfeeding women
• •Evidence of cirrhosis, hepatic decompensation, other than HCV liver disease, HBV or HIV infection
• •Specified abnormalities in lab values of amongst others hemoglobin, WBC, ANC, platelets
• •History of treatment for depression